共 146 条
[1]
Smolen JS(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977
[2]
Landewé R(2016)2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol. 68 1-26
[3]
Bijlsma J(2015)Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE) Arthritis Res Ther. 17 157-629
[4]
Burmester G(2012)Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 617-1905
[5]
Chatzidionysiou K(2009)The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum 60 1895-981
[6]
Dougados M(2012)A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis Rheum 64 970-521
[7]
Singh JA(2015)Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study Mod Rheumatol 25 514-460
[8]
Saag KG(2013)Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised Phase 3 trial Lancet 381 451-507
[9]
Bridges SL(2012)Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 495-261
[10]
Akl EA(2013)Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial Ann Intern Med 159 253-2386